BRPI0915517B8 - método para a produção de um conjugado de vi, conjugado, e, composição farmacêutica - Google Patents

método para a produção de um conjugado de vi, conjugado, e, composição farmacêutica

Info

Publication number
BRPI0915517B8
BRPI0915517B8 BRPI0915517A BRPI0915517A BRPI0915517B8 BR PI0915517 B8 BRPI0915517 B8 BR PI0915517B8 BR PI0915517 A BRPI0915517 A BR PI0915517A BR PI0915517 A BRPI0915517 A BR PI0915517A BR PI0915517 B8 BRPI0915517 B8 BR PI0915517B8
Authority
BR
Brazil
Prior art keywords
conjugate
producing
pharmaceutical composition
crm197
derivatized
Prior art date
Application number
BRPI0915517A
Other languages
English (en)
Inventor
Micoli Francesca
Berti Francesco
Costantino Paolo
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0915517A2 publication Critical patent/BRPI0915517A2/pt
Publication of BRPI0915517B1 publication Critical patent/BRPI0915517B1/pt
Publication of BRPI0915517B8 publication Critical patent/BRPI0915517B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

sacarídeos vi conjugados. dois conjugados de vi foram preparados por síntese mediada por carbodiimida, com o uso de ácido adípico dihidrazida derivatizada crm197 (uma variante não tóxica de toxina diftérica) e toxóide tetânico, como proteínas veículoas.
BRPI0915517A 2008-06-13 2009-06-12 método para a produção de um conjugado de vi, conjugado, e, composição farmacêutica BRPI0915517B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0810894.6 2008-06-13
GBGB0810894.6A GB0810894D0 (en) 2008-06-13 2008-06-13 Conjugated saccharide
PCT/IB2009/006285 WO2009150543A2 (en) 2008-06-13 2009-06-12 Conjugated vi saccharides

Publications (3)

Publication Number Publication Date
BRPI0915517A2 BRPI0915517A2 (pt) 2017-06-20
BRPI0915517B1 BRPI0915517B1 (pt) 2020-10-06
BRPI0915517B8 true BRPI0915517B8 (pt) 2021-05-25

Family

ID=39672273

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0915517A BRPI0915517B8 (pt) 2008-06-13 2009-06-12 método para a produção de um conjugado de vi, conjugado, e, composição farmacêutica

Country Status (18)

Country Link
US (2) US20110142876A1 (pt)
EP (1) EP2303333B1 (pt)
CN (1) CN102089009B (pt)
AU (1) AU2009259017B2 (pt)
BR (1) BRPI0915517B8 (pt)
CA (1) CA2727565C (pt)
CY (1) CY1116379T1 (pt)
DK (1) DK2303333T3 (pt)
ES (1) ES2537019T3 (pt)
GB (1) GB0810894D0 (pt)
HR (1) HRP20150527T1 (pt)
HU (1) HUE025512T2 (pt)
NZ (1) NZ590089A (pt)
PL (1) PL2303333T3 (pt)
PT (1) PT2303333E (pt)
SI (1) SI2303333T1 (pt)
WO (1) WO2009150543A2 (pt)
ZA (1) ZA201009304B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102120761B (zh) * 2010-12-24 2013-02-06 新疆维吾尔自治区畜牧科学院兽医研究所 一种无荚膜型金黄色葡萄球菌胞外多糖-蛋白质偶联物的制备方法
US9358284B2 (en) 2011-09-14 2016-06-07 Glaxosmithkline Biologicals Sa Methods for making saccharide-protein glycoconjugates
RU2684615C2 (ru) * 2013-08-24 2019-04-10 Бхарат Байотек Интернэшнл Лимитед Бактериальная вакцина и способы ее получения
EP2870974A1 (en) * 2013-11-08 2015-05-13 Novartis AG Salmonella conjugate vaccines
EP3448424A4 (en) * 2016-04-25 2019-10-02 National Institute of Immunology NOVEL CONJUGATE FOR THE VACCINATION OF TYPHUS WITH CHEMICAL CONJUGATE OF VI-POLYSACCHARIDE AND FLAGELLIN, METHOD FOR THE PRODUCTION THEREOF AND COMPOSITION WITH THE CONJUGATE
SG11201901394XA (en) 2016-09-02 2019-03-28 Sanofi Pasteur Inc Neisseria meningitidis vaccine
EP4061412A1 (en) 2019-11-22 2022-09-28 GlaxoSmithKline Biologicals S.A. Dosage and administration of a bacterial saccharide glycoconjugate vaccine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL102687A (en) * 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
US5738855A (en) 1994-10-17 1998-04-14 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Synthesis of typhoid fever vaccine from a plant or fruit polysaccharide
US7527797B1 (en) 2000-09-01 2009-05-05 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Vibrio cholerae 0139 conjugate vaccines
WO2003094961A1 (en) * 2002-05-09 2003-11-20 Massimo Porro Improved polysaccharide and glycoconjugate vaccines_____________
US8048432B2 (en) * 2003-08-06 2011-11-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Polysaccharide-protein conjugate vaccines
PT2066344E (pt) * 2006-09-07 2011-07-05 Glaxosmithkline Biolog Sa Vacina de combinação de poliovírus inactivado
GB0700135D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Vaccine

Also Published As

Publication number Publication date
US9475846B2 (en) 2016-10-25
BRPI0915517A2 (pt) 2017-06-20
CN102089009A (zh) 2011-06-08
US20110142876A1 (en) 2011-06-16
PT2303333E (pt) 2015-06-08
WO2009150543A2 (en) 2009-12-17
ZA201009304B (en) 2012-08-29
CA2727565A1 (en) 2009-12-17
DK2303333T3 (da) 2015-05-26
AU2009259017B2 (en) 2014-12-11
CY1116379T1 (el) 2017-02-08
WO2009150543A3 (en) 2010-05-06
US20130142822A1 (en) 2013-06-06
EP2303333B1 (en) 2015-02-18
ES2537019T3 (es) 2015-06-01
NZ590089A (en) 2012-12-21
CA2727565C (en) 2017-01-10
AU2009259017A1 (en) 2009-12-17
SI2303333T1 (sl) 2015-06-30
HUE025512T2 (hu) 2016-05-30
BRPI0915517B1 (pt) 2020-10-06
GB0810894D0 (en) 2008-07-23
EP2303333A2 (en) 2011-04-06
PL2303333T3 (pl) 2015-11-30
CN102089009B (zh) 2013-12-04
HRP20150527T1 (en) 2015-06-19

Similar Documents

Publication Publication Date Title
BRPI0915517B8 (pt) método para a produção de um conjugado de vi, conjugado, e, composição farmacêutica
PE20110065A1 (es) Composiciones y metodos para preparar composiciones inmunogenicas de conjugado de polisacarido capsular de staphylococcus aureus serotipos 5 y 8
CL2016000566A1 (es) Método para para preparar una composición inmunogénica multivalente que comprende 13 conjugados de un serotipo diferente de streptococcus pneumoniae, donde cada uno de los conjugados contiene un polisacárido capsular diferente conjugado a la proteína portadora crm197. div. sol. madre n° 200600802 e hija cl 201702206.
CY1116901T1 (el) Εμβολιο που περιλαμβανει προϊοντα συζευξης καψικου πολυσακχαριδιου streptococcus pneumoniae
AR116043A2 (es) Composición de vacuna conjugada de polisacárido-proteína neumocócica 15-valente
MX354103B (es) Composicion inmunogenica.
AR060187A1 (es) Composicion inmunogenica
PE20120582A1 (es) Conjugados de insulina cristalina
CL2007003781A1 (es) Metodo para la elaboracion de un conjugado inmunogenico que comprende el polisacarido del serotipo 1 de streptococcus pneumoniae covalentemente unido a una proteina vehiculo; y proceso para preparar una composicion inmunogenica multivalente polisacarido-proteina.
BRPI0611872B8 (pt) reagente polimérico, conjugado, método para preparação de um conjugado e composição farmacêutica
GB201101665D0 (en) Immunogenic compositions
BRPI0610359B8 (pt) compostos de diaril-hidantoína, suas composições farmacêuticas e sais farmaceuticamente aceitáveis
NZ600039A (en) Biocompatible biodegradable fumagillin analog conjugates
ECSP13011139A (es) Anticuerpos contra la angiopoyetina 2 humana
EA200800657A1 (ru) Способ приготовления очищенных конъюгатов лекарственных средств
BR112012000569B8 (pt) composição compreendendo um conjugado de benzoato-hidrocodona (bz-hc) e composições para administração oral e intravenosa compreendendo o mesmo
BRPI0715396B8 (pt) método de produção de uma composição para vacina
AR058592A1 (es) Vacuna
BR112016004023A2 (pt) Composição, métodos para preparar uma composição e para tratar uma doença, e, composto
CL2007001648A1 (es) Compuesto derivado de leptomicina; conjugado que comprende agente de unión a células unido a uno o mas de dichos derivados; composiciones farmacéuticas que comprenden dicho derivado o conjugado; util en el tratamiento del cancer; proceso de preparacion de un compuesto o de un conjugado de un derivado de leptomicina.
EA200702577A1 (ru) Способ изготовления вакцин
NZ588884A (en) Cross-linkers and their uses
RU2014151567A (ru) Конъюгат менингококка серогруппы х
CL2012000744A1 (es) Proceso para preparar un conjugado de polisacáridos capsulares tipo 5 o tipo 8 de s. aureus y una molécula transportadora; conjugado de polisacáridos; y composición inmunogénica que lo comprende.
AR092897A1 (es) Composiciones inmunogenicas

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 47/00 (2006.01), A61P 43/00 (2006.01)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/10/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/06/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25A Requested transfer of rights approved

Owner name: GLAXOSMITHKLINE BIOLOGICALS S.A. (BE)